3.86
前日終値:
$3.88
開ける:
$3.92
24時間の取引高:
2.99M
Relative Volume:
0.64
時価総額:
$1.01B
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-13.79
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-1.91%
1か月 パフォーマンス:
+8.29%
6か月 パフォーマンス:
+86.23%
1年 パフォーマンス:
+183.46%
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AKBA
Akebia Therapeutics Inc
|
3.86 | 1.05B | 194.75M | -51.26M | -23.38M | -0.28 |
![]()
ZTS
Zoetis Inc
|
148.60 | 70.70B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 46.87B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.60 | 45.41B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.06 | 18.96B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
292.01 | 13.54B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-04 | 再開されました | H.C. Wainwright | Buy |
2025-04-28 | 開始されました | Leerink Partners | Outperform |
2025-04-01 | 開始されました | Jefferies | Buy |
2023-11-29 | 再開されました | BTIG Research | Buy |
2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-31 | ダウングレード | Needham | Buy → Hold |
2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-11-14 | 繰り返されました | Needham | Buy |
2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
2019-05-02 | 開始されました | JP Morgan | Overweight |
2019-03-20 | 開始されました | Citigroup | Neutral |
2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
2018-08-10 | 繰り返されました | Needham | Buy |
2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
2017-12-19 | 開始されました | Piper Jaffray | Overweight |
2017-12-07 | 開始されました | BTIG Research | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-27 | 繰り返されました | Needham | Buy |
2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
2016-11-15 | 開始されました | Aegis Capital | Buy |
2016-09-29 | 開始されました | Brean Capital | Buy |
2016-03-16 | 繰り返されました | Needham | Buy |
2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
What analysts say about Akebia Therapeutics Inc. stockStrongest growth potential - Jammu Links News
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GATO, AKBA and LCID - ACCESS Newswire
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
PHD inhibitors reported in Akebia Therapeutics patent - BioWorld MedTech
Transcript : Akebia Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 10 - MarketScreener
Akebia at H.C. Wainwright: Strategic Insights on Kidney Care Products By Investing.com - Investing.com Canada
Akebia Ther stock hits 52-week high at 4.08 USD - Investing.com Australia
Akebia Ther stock hits 52-week high at 4.08 USD By Investing.com - Investing.com Nigeria
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire
Upcoming Kidney Disease Conference: Akebia CCO to Share Latest Commercial Strategy - Stock Titan
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - Insider Monkey
13 Stocks Under $5 With High Upside Potential - Insider Monkey
Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price - Stock Titan
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st
AVEROA - The Pharma Letter
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Akebia Therapeutics expands stock incentive plan - Investing.com Australia
Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa
Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks
Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha
Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN
Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa
Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha
Akebia reports mixed results for anemia drug in global study - Investing.com Australia
Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus
Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus
Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq
Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance
H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com
Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus
Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa
Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):